Ert Pompe denied as experimental or investigational by AmeriHealth Caritas?

Confirmed enzyme assay + genetic testing. Specialist Rx (geneticist or metabolic).

EPSDT for under-21 overrides state PDL limits. Orphan Drug Act + FDA approval rebut 'experimental' label. Site-of-care: home infusion appropriate for stable patients per manufacturer REMS.

## Why AmeriHealth Caritas Denies ERT for Pompe Disease as Experimental — and Why This Denial Is Challengeable

Enzyme replacement therapy for Pompe disease has held FDA approval for treating this lysosomal storage disorder for many years. An "experimental" or "investigational" denial for ERT in Pompe disease is therefore factually incorrect when the drug is being prescribed within its FDA-approved indication. This type of denial is most commonly a system error — an automated coverage-screening tool that flags biologics or high-cost infusion drugs without recognizing the specific FDA approval — or it may reflect an outdated coverage policy.

If the denial letter cites experimental status for a drug with a confirmed FDA approval and the patient's use matches the approved indication, the appeal argument is straightforward: the drug is not experimental, and the denial rests on a factual error.

## Federal Appeal Rights

Experimental or investigational determinations are explicitly covered under the appeal rights created by ACA Section 2719 (commercial plans) and ERISA Section 503 (employer plans). For AmeriHealth Caritas Medicaid/CHIP enrollees, parallel state Medicaid appeal rights and the right to a state fair hearing apply. External review by an Independent Review Organization is available after internal exhaustion for commercial plans — and external reviewers are specifically empowered to evaluate whether an "experimental" classification is scientifically current and appropriate. The external-review window is generally within 4 months of the final internal denial.

## Appeal Process and Timeline

1. Obtain the specific experimental determination — request the clinical evidence or policy language AmeriHealth Caritas used to classify ERT for Pompe disease as experimental. 2. Internal appeal — attach the FDA approval documentation (the current prescribing label from the FDA's Drugs@FDA database) showing the approved indication. Request that the experimental classification be rescinded. 3. Peer-to-peer review — the treating metabolic specialist or neurologist should request a direct call with AmeriHealth Caritas's medical director to walk through the FDA approval history. 4. External review / state fair hearing — if the internal appeal is denied, an external reviewer or state hearing officer can independently verify FDA approval status.

## Documentation to Gather

• FDA approval documentation: the current prescribing label for the specific ERT product (alglucosidase alfa or avalglucosidase alfa) showing the approved indication and date of approval.
• Confirmed Pompe disease diagnosis: GAA gene variant testing results and/or enzyme activity assay confirming the diagnosis.
• Prescriber letter: from the treating metabolic disease specialist stating that the drug is FDA-approved for the patient's confirmed diagnosis, that it is being prescribed within the approved indication, and that it is the standard of care per the applicable specialist-society guidelines on Pompe disease management.
• Clinical records: current assessment of disease severity, including cardiorespiratory and motor function, to document the medical necessity alongside the experimental-status rebuttal.

## Criteria-Mapping Structure

Pull AmeriHealth Caritas's experimental/investigational policy and map: (1) FDA approval status — attach prescribing label; (2) Indication match — confirm patient's diagnosis aligns with the approved indication language; (3) Standard of care — reference the relevant metabolic disease or neuromuscular specialist-society guidance (without citing specific statistics); (4) Cigna's stated experimental criteria — address each criterion with the above documentation. An experimental denial that cannot point to an absence of FDA approval or a defined investigational use is extremely difficult to sustain on external review.